Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 11/20 | 0.62 |
| ▸ | EML4 | Q9HC35 | 4/20 | 0.62 |
| ▸ | TTK | P33981 | 5/20 | 0.54 |
| ▸ | IGF1R | P08069 | 2/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | ROS1 | P08922 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10156861 | 0.90 | ALK (0.73) | ALKEML4TTKIGF1RRET | |
| SCHEMBL10129301 | 0.86 | ALK (0.84) | ALKEML4IGF1RRETROS1 | |
| SCHEMBL10156896 | 0.82 | ALK (0.61) | ALKEML4TTKIGF1RRET | |
| SCHEMBL10156955 | 0.82 | ALK (0.61) | ALKEML4IGF1RRETROS1 | |
| SCHEMBL282104 | 0.77 | EML4 (1.00) | ALKEML4RETROS1FLT3 | |
| SCHEMBL282103 | 0.77 | EML4 (1.00) | ALKEML4RETROS1FLT3 | |
| SCHEMBL10156298 | 0.75 | ALK (0.77) | ALKEML4IGF1RRETROS1 | |
| SCHEMBL10129251 | 0.75 | ALK (0.77) | ALKEML4IGF1RRETROS1 | |
| SCHEMBL10126771 | 0.75 | ALK (0.63) | ALKEML4IGF1RRETROS1 | |
| SCHEMBL10129248 | 0.74 | ALK (0.85) | ALKEML4RETROS1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | WATERS TECHNOLOGIES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040968-A1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | EML4, ALK, ERBB4 | ALK 2/4885EML4 1/4885TTK 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.